Development of orally active inhibitors of protein and cellular fucosylation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5404-5409

  Okeley, Nicole M ^a   Alley, Stephen C ^a   Anderson, Martha E ^a   Boursalian, Tamar E ^a   Burke, Patrick J ^a   Emmerton, Kim M ^a   Jeffrey, Scott C ^a   Klussman, Kerry ^a   Law, Che Leung ^a   Sussman, Django ^a   Toki, Brian E ^a   Westendorf, Lori ^a   Zeng, Weiping ^a   Zhang, Xinqun ^a   Benjamin, Dennis R ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

Carbohydrate; Glycosylation; Metabolism; Selectin

Indexed keywords

2 FLUOROFUCOSE; 5 ALKYNYLFUCOSE; FUCOSE; FUCOSYLTRANSFERASE; GLYCAN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; FEMALE; FUCOSYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CELL LINE, TUMOR; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETINAE; CRICETULUS; DRUG DESIGN; FEMALE; FUCOSE; FUCOSYLTRANSFERASES; GUANOSINE DIPHOSPHATE FUCOSE; HUMANS; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEUTROPHILS; POLYSACCHARIDES;

MUS;

EID: 84875837494     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222263110     Document Type: Article

References (53)

1. Agard NJ, Bertozzi CR (2009) Chemical approaches to perturb, profile, and perceive glycans. Acc Chem Res 42(6):788-797.
2. Gloster TM, Vocadlo DJ (2012) Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. Nat Chem Biol 8(8):683-694.
3. Kiessling LL, Splain RA (2010) Chemical approaches to glycobiology. Annu Rev Biochem 79:619-653.
4. Rabinovich GA, van Kooyk Y, Cobb BA (2012) Glycobiology of immune responses. Ann N Y Acad Sci 1253:1-15.
5. Hoffmeister KM (2011) The role of lectins and glycans in platelet clearance. J Thromb Haemost 9(Suppl 1):35-43.
6. Moriwaki K, Miyoshi E (2010) Fucosylation and gastrointestinal cancer. World J Hepatol 2(4):151-161.
7. Brown CD, Rusek MS, Kiessling LL (2012) Fluorosugar chain termination agents as probes of the sequence specificity of a carbohydrate polymerase. J Am Chem Soc 134(15):6552-6555.
8. Du J, et al. (2009) Metabolic glycoengineering: sialic acid and beyond. Glycobiology 19(12):1382-1401.
9. Fuster MM, Brown JR, Wang L, Esko JD (2003) A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 63(11):2775-2781.
10. Hsu TL, et al. (2007) Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells. Proc Natl Acad Sci USA 104(8):2614-2619.
11. Rillahan CD, et al. (2012) Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 8(7):661-668.
12. Sawa M, et al. (2006) Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proc Natl Acad Sci USA 103(33):12371-12376.
13. Gloster TM, et al. (2011) Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat Chem Biol 7(3):174-181.
14. Chaubard JL, Krishnamurthy C, Yi W, Smith DF, Hsieh-Wilson LC (2012) Chemoenzymatic probes for detecting and imaging fucose-a(1-2)-galactose glycan biomarkers. J Am Chem Soc 134(10):4489-4492.
15. Barthel SR, et al. (2011) Peracetylated 4-fluoro-glucosamine reduces the content and repertoire of N- and O-glycans without direct incorporation. J Biol Chem 286(24): 21717-21731.
16. Zandberg WF, Kumarasamy J, Pinto BM, Vocadlo DJ (2012) Metabolic inhibition of sialyl-Lewis X biosynthesis by 5-thiofucose remodels the cell surface and impairs selectin-mediated cell adhesion. J Biol Chem 287(47):40021-40030.
17. Alley SC, et al. (2012) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation. US Patent 8, 163, 551.
18. Saul R, Chambers JP, Molyneux RJ, Elbein AD (1983) Castanospermine, a tetrahydroxylated alkaloid that inhibits beta-glucosidase and beta-glucocerebrosidase. Arch Biochem Biophys 221(2):593-597.
19. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW (1994) A phase I study of swainsonine in patients with advanced malignancies. Cancer Res 54(6):1450-1457.
20. Platt FM, Neises GR, Dwek RA, Butters TD (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269(11):8362-8365.
21. Becker DJ, Lowe JB (2003) Fucose: Biosynthesis and biological function in mammals. Glycobiology 13(7):41R-53R.
22. Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8(3):226-234.
23. Jiang XR, et al. (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10(2):101-111.
24. Reichert JM, Dhimolea E (2012) The future of antibodies as cancer drugs. Drug Discov Today 17(17-18):954-963.
25. Salles G, et al. (2012) Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22):5126-5132.
26. Scallon B, et al. (2007) Quantitative in vivo comparisons of the Fc gamma receptordependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Int Immunopharmacol 7(6):761-772.
27. Shields RL, et al. (2001) High resolution mapping of the binding site on human IgG1 for Fc RI, Fc RII, Fc RIII, and FcRn and design of IgG1 variants with improved binding to the Fc R. J Biol Chem 276(9):6591-6604.
28. Beck A, Reichert JM (2012) Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 4(4):419-425.
29. Miyoshi E, Moriwaki K, Nakagawa T (2008) Biological function of fucosylation in cancer biology. J Biochem 143(6):725-729.
30. Chen CY, et al. (2013) Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci USA 110(2):630-635.
31. McEarchern JA, et al. (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109(3):1185-1192.
32. Ihara H, Ikeda Y, Taniguchi N (2006) Reaction mechanism and substrate specificity for nucleotide sugar of mammalian alpha1, 6-fucosyltransferase-a large-scale preparation and characterization of recombinant human FUT8. Glycobiology 16(4):333-342.
33. Matsumura K, et al. (2007) Carbohydrate binding specificity of a fucose-specific lectin from Aspergillus oryzae: A novel probe for core fucose. J Biol Chem 282(21): 15700-15708.
34. Trail PA, et al. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261(5118):212-215.
35. Yoshida-Noro C, Heasman J, Goldstone K, Vickers L, Wylie C (1999) Expression of the Lewis group carbohydrate antigens during Xenopus development. Glycobiology 9(12):1323-1330.
36. Stümpel F, Burcelin R, Jungermann K, Thorens B (2001) Normal kinetics of intestinal glucose absorption in the absence of GLUT2: Evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum. Proc Natl Acad Sci USA 98(20):11330-11335.
37. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM (2008) Sulfhydrylbased tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol 181(6):4131-4140.
38. Briones J, Timmerman JM, Panicalli DL, Levy R (2003) Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 95(7):548-555.
39. Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW (2012) Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice. Blood 119(9):2056-2065.
40. Bernstein ID, Tam MR, Nowinski RC (1980) Mouse leukemia: Therapy with monoclonal antibodies against a thymus differentiation antigen. Science 207(4426):68-71.
41. Campbell MJ, et al. (1987) Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139(8):2825-2833.
42. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN (1972) Myeloma proteins as tumorspecific transplantation antigens. Proc Natl Acad Sci USA 69(6):1540-1544.
43. Wimmerova M, Mitchell E, Sanchez JF, Gautier C, Imberty A (2003) Crystal structure of fungal lectin: Six-bladed beta-propeller fold and novel fucose recognition mode for Aleuria aurantia lectin. J Biol Chem 278(29):27059-27067.
44. Forlow SB, Foley PL, Ley K (2002) Severely reduced neutrophil adhesion and impaired host defense against fecal and commensal bacteria in CD18-/-P-selectin-/- double null mice. FASEB J 16(12):1488-1496.
45. Malý P, et al. (1996) The alpha(1, 3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 86(4):643-653.
46. Levy AL, Waldmann TA (1970) The effect of hydrocortisone on immunoglobulin metabolism. J Clin Invest 49(9):1679-1684.
47. von Vietinghoff S, Ley K (2008) Homeostatic regulation of blood neutrophil counts. J Immunol 181(8):5183-5188.
48. Harsh GR, Nishimura RN, Dwyer BE, Levin VA (1986) L-fucose labeling of brain tumors in rats. Exp Neurol 94(1):21-28.
49. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 22(23): 4717-4724.
50. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21(21):3940-3947.
51. Forthal DN, et al. (2010) Fc-glycosylation influences Fcγ receptor binding and cellmediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 185(11): 6876-6882.
52. McDonagh CF, et al. (2008) Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 7(9):2913-2923.
53. Du Y, May K, Xu W, Liu H (2012) Detection and quantitation of afucosylated N-linked oligosaccharides in recombinant monoclonal antibodies using enzymatic digestion and LC-MS. J Am Soc Mass Spectrom 23(7):1241-1249.